JOHNS HOPKINS UNIVERSITY INVESTIGATOR SPONSORED CLINICAL PROOF OF CONCEPT TRIAL
A randomized controlled phase 2 study of generic oral itraconazole in patients with metastatic non-squamous non-small cell lung cancer (NS NSCLS). A two-arm study: combination with standard dose of second-line Pemetrexed.
Conclusions consisted of an improved median survival from 8 months to 32 months, it was well tolerated with grade 3 toxicity related to Pemetrexed (in 5 patients total). Itraconazole as an oral therapy may extend survival in patients with an unmet need.
As part of this ‘window-of-opportunity’ trial itraconazole demonstrated concentration-dependent early anti-vascular, metabolic, and antitumor effects in patients with NSCLC. Itraconazole was well-tolerated. Steady state plasma concentrations of itraconazole and hydroxyitraconazole demonstrated a 6-fold difference across patients. Tumor itraconazole concentrations trended with and exceeded those of plasma.
